Lymphoma

Latest News

3 Things You Should Know About Immunotherapy in DLBCL
3 Things You Should Know About Immunotherapy in DLBCL

December 19th 2024

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia
Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

December 13th 2024

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.
PFS Boost Occurs With Tafasitamab Combo in R/R Follicular Lymphoma

December 11th 2024

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.
No Clinical Benefit Added Using Auto-HCT/Rituximab in MCL Cohort

December 10th 2024

Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL
Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL

December 10th 2024